Tech takes VC so start-ups look to BIRAC as Indian 'messiah'
This article was originally published in Scrip
With venture capital funds (VCs) behaving almost like bankers when it comes to investing in Indian biotech, the government has emerged as the new "messiah" for start-ups in the sector, according to Dr P M Murali, president of the Association of Biotechnology Led Enterprises (ABLE) and managing director and CEO of Evolva Biotech.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.